Customize your JAMA Network experience by selecting one or more topics from the list below.
Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708–1709. doi:10.1001/jama.2017.11909
There is growing consumer demand for cannabidiol (CBD), a constituent of the cannabis plant, due to its purported medicinal benefits for myriad health conditions.1 Viscous plant-derived extracts, suspended in oil, alcohol (tincture), or vaporization liquid, represent most of the retail market for CBD. Discrepancies between federal and state cannabis laws have resulted in inadequate regulation and oversight, leading to inaccurate labeling of some products.2 To maximize sampling and ensure representativeness of available products, we examined the label accuracy of CBD products sold online, including identification of present but unlabeled cannabinoids.
Internet searches (keywords: CBD, cannabidiol, oil, tincture, vape) were performed between September 12, 2016, and October 15, 2016, to identify CBD products available for online retail purchase that included CBD content on packaging. Products with identical formulation as another product under the same brand were excluded. All unique CBD extracts that met these criteria were purchased. Products were stored according to packaging instructions, or if none were provided, in a cool, dry space. Within 2 weeks of receipt, product labels were replaced with blinded study identifiers and sent to the laboratories at Botanacor Services for analysis of cannabinoid content (cannabidiol, cannabidiolic acid, cannabigerol, cannabinol, Δ-9-tetrahydrocannabinol, Δ-9-tetrahydrocannabibolic acid [THC]) using high-performance liquid chromatography (in triplicate; lower limit of quantification, ≤0.3170% wt/wt). A 10-point method validation procedure was used to determine the appropriate sample preparation and analytical method. Triplicate test results were averaged and reported by product weight. Data were analyzed using SPSS Statistics (IBM), version 23, with descriptive analyses and a 2-tailed χ2 (α <.05). Consistent with other herbal products in the US Pharmacopeia and emerging standards from medicinal cannabis industry leaders, a ±10% allowable variance was used for product labeling (ie, accurately labeled = 90%-110% labeled value, underlabeled >110% labeled value, and overlabeled <90% labeled value).
Eighty-four products were purchased and analyzed (from 31 companies). Observed CBD concentration ranged between 0.10 mg/mL and 655.27 mg/mL (median, 9.45 mg/mL). Median labeled concentration was 15.00 mg/mL (range, 1.33-800.00). With respect to CBD, 42.85% (95% CI, 32.82%-53.53%) of products were underlabeled (n = 36), 26.19% (95% CI, 17.98%-36.48%) were overlabeled (n = 22), and 30.95% (95% CI, 22.08%-41.49%) were accurately labeled (n = 26) (Table 1). Accuracy of labeling depended on product type [χ2(1) = 16.75; P = .002], with vaporization liquid most frequently mislabeled (21 mislabeled products; 87.50% [95% CI, 69.00%-95.66%]) and oil most frequently labeled accurately (18 accurately labeled products; 45.00% [95% CI, 30.71%-60.17%]). Concentration of unlabeled cannabinoids was generally low (Table 2); however, THC was detected (up to 6.43 mg/mL) in 18 of the 84 samples tested (21.43% [95% CI, 14.01%-31.35%]), cannabidiolic acid (up to 55.73 mg/mL) in 13 of the 84 samples tested (15.48% [95% CI, 9.28%-24.70%]), and cannabigerol (up to 4.67 mg/mL) in 2 of the 84 samples tested (2.38% [95% CI, 0.65%-8.27%]).
Among CBD products purchased online, a wide range of CBD concentrations was found, consistent with the lack of an accepted dose. Of tested products, 26% contained less CBD than labeled, which could negate any potential clinical response. The overlabeling of CBD products in this study is similar in magnitude to levels that triggered warning letters to 14 businesses in 2015-2016 from the US Food and Drug Administration3 (eg, actual CBD content was negligible or less than 1% of the labeled content), suggesting that there is a continued need for federal and state regulatory agencies to take steps to ensure label accuracy of these consumer products. Underlabeling is less concerning as CBD appears to neither have abuse liability nor serious adverse consequences at high doses4,5; however, the THC content observed may be sufficient to produce intoxication or impairment, especially among children.6 Although the exclusive procurement of products online is a study limitation given the frequently changing online marketplace, these products represent the most readily available to US consumers. Additional monitoring should be conducted to determine changes in this marketplace over time and to compare internet products with those sold in dispensaries. These findings highlight the need for manufacturing and testing standards, and oversight of medicinal cannabis products.
Correction: This article was corrected for missing Funding/Support, Role of the Sponsors, and Additional Contributions statements on December 5, 2017.
Accepted for Publication: August 7, 2017.
Corresponding Author: Marcel O. Bonn-Miller, PhD, University of Pennsylvania Perelman School of Medicine, 3440 Market St, Ste 370, Philadelphia, PA 19104 (firstname.lastname@example.org).
Author Contributions: Dr Bonn-Miller had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bonn-Miller, Loflin, Thomas, Vandrey.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Bonn-Miller, Loflin, Marcu, Vandrey.
Critical revision of the manuscript for important intellectual content: Bonn-Miller, Loflin, Thomas, Hyke, Vandrey.
Statistical analysis: Loflin, Marcu.
Obtained funding: Bonn-Miller.
Administrative, technical, or material support: Bonn-Miller, Loflin, Thomas, Hyke, Vandrey.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Bonn-Miller, Thomas, and Vandrey reported serving as unpaid board members of the Institute for Research on Cannabinoids. Dr Bonn-Miller reported receiving personal fees from Zynerba Pharmaceuticals, the Lambert Center for the Study of Medicinal Cannabis and Hemp, the Realm of Caring Foundation, Tilray, CW Botanicals, Insys Therapeutics, International Cannabis and Cannabinoids Institute, the Medical Cannabis Institute, and Aphria. Dr Vandrey reported receiving personal fees from Zynerba Pharmaceuticals, CW Hemp, Battelle Memorial Institute, and Insys Pharmaceuticals. No other disclosures were reported.
Funding/Support: This project was funded by a grant from the Institute for Research on Cannabinoids (IROC), a 501(c)(3) nonprofit organization supported by individual donations.
Role of the Funder/Sponsor: Although Drs Bonn-Miller, Thomas, and Vandrey serve as unpaid board members of IROC, the institution played no part in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Additional Contributions: We thank the Realm of Caring Foundation for their facility and staff support for the execution of this project. They did not receive compensation for their contribution.